{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:51:45Z","timestamp":1761339105482,"version":"build-2065373602"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Support Object of AMU","award":["No. 410301060133"],"award-info":[{"award-number":["No. 410301060133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06276-w","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:19:48Z","timestamp":1758734388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway"],"prefix":"10.1007","volume":"151","author":[{"given":"Bingqian","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Langlang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"6276_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R.L., A.N. Giaquinto and A. Jemal Cancer statistics, 2024. CA Cancer J Clin, 2024. 74(1) https:\/\/doi.org\/10.3322\/caac.21820.","DOI":"10.3322\/caac.21820"},{"key":"6276_CR2","doi-asserted-by":"publisher","unstructured":"Sharifi, N., J.L. Gulley and W.L. Dahut Androgen deprivation therapy for prostate cancer. Jama, 2005. 294(2) https:\/\/doi.org\/10.1001\/jama.294.2.238.","DOI":"10.1001\/jama.294.2.238"},{"key":"6276_CR3","doi-asserted-by":"publisher","unstructured":"Miller, C.D., P. Likasitwatanakul, E. Toye, et al. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment. Expert Rev Anticancer Ther, 2024. 24(11) https:\/\/doi.org\/10.1080\/14737140.2024.2405103.","DOI":"10.1080\/14737140.2024.2405103"},{"key":"6276_CR4","doi-asserted-by":"publisher","unstructured":"Antonarakis, E.S., C. Lu, H. Wang, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med, 2014. 371(11) https:\/\/doi.org\/10.1056\/NEJMoa1315815.","DOI":"10.1056\/NEJMoa1315815"},{"key":"6276_CR5","doi-asserted-by":"publisher","unstructured":"Zhu, Y., S.L. Dalrymple, I. Coleman, et al. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene, 2020. 39(45) https:\/\/doi.org\/10.1038\/s41388-020-01479-6.","DOI":"10.1038\/s41388-020-01479-6"},{"key":"6276_CR6","doi-asserted-by":"publisher","unstructured":"Korpal, M., J.M. Korn, X. Gao, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov, 2013. 3(9) https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0142.","DOI":"10.1158\/2159-8290.Cd-13-0142"},{"key":"6276_CR7","doi-asserted-by":"publisher","unstructured":"Liu, C., J.C. Yang, C.M. Armstrong, et al. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther, 2019. 18(10) https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-1322.","DOI":"10.1158\/1535-7163.Mct-18-1322"},{"key":"6276_CR8","doi-asserted-by":"publisher","unstructured":"Ning, S., C.M. Armstrong, E. Xing, et al. LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Res, 2024. 84(21) https:\/\/doi.org\/10.1158\/0008-5472.Can-24-0440.","DOI":"10.1158\/0008-5472.Can-24-0440"},{"key":"6276_CR9","doi-asserted-by":"publisher","unstructured":"Liu, C., C.M. Armstrong, W. Lou, et al. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther, 2017. 16(1) https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0186.","DOI":"10.1158\/1535-7163.Mct-16-0186"},{"key":"6276_CR10","doi-asserted-by":"publisher","unstructured":"Arora, V.K., E. Schenkein, R. Murali, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 2013. 155(6) https:\/\/doi.org\/10.1016\/j.cell.2013.11.012.","DOI":"10.1016\/j.cell.2013.11.012"},{"key":"6276_CR11","doi-asserted-by":"publisher","unstructured":"Bluemn, E.G., I.M. Coleman, J.M. Lucas, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell, 2017. 32(4) https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003.","DOI":"10.1016\/j.ccell.2017.09.003"},{"key":"6276_CR12","doi-asserted-by":"publisher","unstructured":"Chen, X., L. Yin, H. Xu, et al. Knockdown of RhoA Expression Reverts Enzalutamide Resistance via the p38 MAPK Pathway in Castration-resistant Prostate Cancer. Recent Pat Anticancer Drug Discov, 2023. 18(1) https:\/\/doi.org\/10.2174\/1574892817666220325151555.","DOI":"10.2174\/1574892817666220325151555"},{"key":"6276_CR13","doi-asserted-by":"publisher","unstructured":"Panja, S., M.I. Truica, C.Y. Yu, et al. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nat Commun, 2024. 15(1) https:\/\/doi.org\/10.1038\/s41467-024-44686-5.","DOI":"10.1038\/s41467-024-44686-5"},{"key":"6276_CR14","doi-asserted-by":"publisher","unstructured":"Davies, A.H., H. Beltran and A. Zoubeidi Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol, 2018. 15(5) https:\/\/doi.org\/10.1038\/nrurol.2018.22.","DOI":"10.1038\/nrurol.2018.22"},{"key":"6276_CR15","doi-asserted-by":"publisher","unstructured":"Westbrook, T.C., X. Guan, E. Rodansky, et al. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun, 2022. 13(1) https:\/\/doi.org\/10.1038\/s41467-022-32701-6.","DOI":"10.1038\/s41467-022-32701-6"},{"key":"6276_CR16","doi-asserted-by":"publisher","unstructured":"Apte, R.S., D.S. Chen and N. Ferrara VEGF in Signaling and Disease: Beyond Discovery and Development. Cell, 2019. 176(6) https:\/\/doi.org\/10.1016\/j.cell.2019.01.021.","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"6276_CR17","doi-asserted-by":"publisher","unstructured":"Xie, Y., N. Su, J. Yang, et al. FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther, 2020. 5(1) https:\/\/doi.org\/10.1038\/s41392-020-00222-7.","DOI":"10.1038\/s41392-020-00222-7"},{"key":"6276_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","volume":"202","author":"X Zou","year":"2022","unstructured":"Zou X, Tang XY, Qu ZY et al (2022) Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: a review. Int J Biol Macromol 202:539\u2013557. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.01.113","journal-title":"Int J Biol Macromol"},{"issue":"3\u20134","key":"6276_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/08977194.2019.1662415","volume":"37","author":"A Bottrell","year":"2019","unstructured":"Bottrell A, Meng YH, Najy AJ et al (2019) An oncogenic activity of PDGF-C and its splice variant in human breast cancer. Growth Factors 37(3\u20134):131\u2013145. https:\/\/doi.org\/10.1080\/08977194.2019.1662415","journal-title":"Growth Factors"},{"issue":"40","key":"6276_CR20","doi-asserted-by":"publisher","first-page":"2407069","DOI":"10.1002\/advs.202407069","volume":"11","author":"YH Shi","year":"2024","unstructured":"Shi YH, Liu ZD, Ma MJ et al (2024) Platelet-derived growth factor C facilitates malignant behavior of pancreatic ductal adenocarcinoma by regulating SREBP1 mediated lipid metabolism. Adv Sci (Weinh) 11(40):2407069. https:\/\/doi.org\/10.1002\/advs.202407069","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"6276_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2022.11.004","volume":"31","author":"YH Shi","year":"2023","unstructured":"Shi YH, Xu QC, Zhu YQ et al (2023) Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Mol Ther 31(2):503\u2013516. https:\/\/doi.org\/10.1016\/j.ymthe.2022.11.004","journal-title":"Mol Ther"},{"issue":"11","key":"6276_CR22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41388-021-01685-w","volume":"40","author":"H Yoon","year":"2021","unstructured":"Yoon H, Tang CM, Banerjee S et al (2021) Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene 40(11):1957\u20131973. https:\/\/doi.org\/10.1038\/s41388-021-01685-w","journal-title":"Oncogene"},{"issue":"1","key":"6276_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12931-023-02532-0","volume":"24","author":"N Zhang","year":"2023","unstructured":"Zhang N, Liu Z, Lai X et al (2023) Silencing of CD147 inhibits cell proliferation, migration, invasion, lipid metabolism dysregulation and promotes apoptosis in lung adenocarcinoma via blocking the Rap1 signaling pathway. Respir Res 24(1):253. https:\/\/doi.org\/10.1186\/s12931-023-02532-0","journal-title":"Respir Res"},{"key":"6276_CR24","doi-asserted-by":"publisher","unstructured":"Shah S, Brock EJ, Ji K et al (2019) Ras and Rap1: A tale of two GTPases. In: Seminars in cancer biology, vol 54https:\/\/doi.org\/10.1016\/j.semcancer.2018.03.005.","DOI":"10.1016\/j.semcancer.2018.03.005"},{"issue":"29","key":"6276_CR25","doi-asserted-by":"publisher","first-page":"27406","DOI":"10.1074\/jbc.M101056200","volume":"276","author":"DG Gilbertson","year":"2001","unstructured":"Gilbertson DG, Duff ME, West JW et al (2001) Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 276(29):27406\u201327414. https:\/\/doi.org\/10.1074\/jbc.M101056200","journal-title":"J Biol Chem"},{"key":"6276_CR26","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.neo.2024.101047","volume":"57","author":"J Hu","year":"2024","unstructured":"Hu J, Zhang J, Han B et al (2024) PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway. Neoplasia 57:101047. https:\/\/doi.org\/10.1016\/j.neo.2024.101047","journal-title":"Neoplasia"},{"issue":"8","key":"6276_CR27","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1111\/cas.16239","volume":"115","author":"B Huang","year":"2024","unstructured":"Huang B, Deng X, Zhou G et al (2024) SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance. Cancer Sci 115(8):2630\u20132645. https:\/\/doi.org\/10.1111\/cas.16239","journal-title":"Cancer Sci"},{"issue":"5","key":"6276_CR28","doi-asserted-by":"publisher","first-page":"100608","DOI":"10.1016\/j.xcrm.2022.100608","volume":"3","author":"Z Mei","year":"2022","unstructured":"Mei Z, Yang T, Liu Y et al (2022) Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment. Cell Rep Med 3(5):100608. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100608","journal-title":"Cell Rep Med"},{"issue":"Pt 2","key":"6276_CR29","doi-asserted-by":"publisher","first-page":"129635","DOI":"10.1016\/j.ijbiomac.2024.129635","volume":"260","author":"Y Yao","year":"2024","unstructured":"Yao Y, Chen X, Wang X et al (2024) Glycolysis related lncRNA SNHG3\/miR-139\u20135p\/PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance. Int J Biol Macromol 260(Pt 2):129635. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129635","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"6276_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s11658-024-00628-z","volume":"29","author":"X Cheng","year":"2024","unstructured":"Cheng X, Yang H, Chen Y et al (2024) METTL3-mediated m(6)A modification of circGLIS3 promotes prostate cancer progression and represents a potential target for ARSI therapy. Cell Mol Biol Lett 29(1):109. https:\/\/doi.org\/10.1186\/s11658-024-00628-z","journal-title":"Cell Mol Biol Lett"},{"issue":"12","key":"6276_CR31","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/cbin.12082","volume":"47","author":"J Li","year":"2023","unstructured":"Li J, Hu W, Zhang R et al (2023a) PDGF-C promotes cell proliferation partially via downregulating BOP1. Cell Biol Int 47(12):1942\u20131949. https:\/\/doi.org\/10.1002\/cbin.12082","journal-title":"Cell Biol Int"},{"key":"6276_CR32","doi-asserted-by":"publisher","first-page":"4708076","DOI":"10.1155\/2017\/4708076","volume":"2017","author":"RM Manzat Saplacan","year":"2017","unstructured":"Manzat Saplacan RM, Balacescu L, Gherman C et al (2017) The role of PDGFs and PDGFRs in colorectal cancer. Mediators Inflamm 2017:4708076. https:\/\/doi.org\/10.1155\/2017\/4708076","journal-title":"Mediators Inflamm"},{"issue":"01","key":"6276_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4236\/jct.2014.51002","volume":"5","author":"S Yamauchi","year":"2014","unstructured":"Yamauchi S, Iida S, Ishiguro M et al (2014) Clinical significance of platelet-derived growth factor-C expression in colorectal cancer. J Cancer Ther 5(01):11. https:\/\/doi.org\/10.4236\/jct.2014.51002","journal-title":"J Cancer Ther"},{"issue":"4","key":"6276_CR34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s43018-023-00525-y","volume":"4","author":"FK Turrell","year":"2023","unstructured":"Turrell FK, Orha R, Guppy NJ et al (2023) Age-associated microenvironmental changes highlight the role of PDGF-C in ER(+) breast cancer metastatic relapse. Nat Cancer 4(4):468\u2013484. https:\/\/doi.org\/10.1038\/s43018-023-00525-y","journal-title":"Nat Cancer"},{"key":"6276_CR35","doi-asserted-by":"publisher","first-page":"173868","DOI":"10.1016\/j.ejphar.2021.173868","volume":"895","author":"S Kim","year":"2021","unstructured":"Kim S, You D, Jeong Y et al (2021) Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells. Eur J Pharmacol 895:173868. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173868","journal-title":"Eur J Pharmacol"},{"key":"6276_CR36","doi-asserted-by":"publisher","first-page":"106782","DOI":"10.1016\/j.phrs.2023.106782","volume":"192","author":"F Ruffini","year":"2023","unstructured":"Ruffini F, Ceci C, Atzori MG et al (2023) Targeting of PDGF-C\/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors. Pharmacol Res 192:106782. https:\/\/doi.org\/10.1016\/j.phrs.2023.106782","journal-title":"Pharmacol Res"},{"issue":"5","key":"6276_CR37","doi-asserted-by":"publisher","first-page":"109674","DOI":"10.1016\/j.isci.2024.109674","volume":"27","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Yu SL, Xie ZX et al (2024) Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience 27(5):109674. https:\/\/doi.org\/10.1016\/j.isci.2024.109674","journal-title":"iScience"},{"issue":"4","key":"6276_CR38","doi-asserted-by":"publisher","first-page":"e20221007","DOI":"10.1084\/jem.20221007","volume":"220","author":"XF Li","year":"2023","unstructured":"Li XF, Selli C, Zhou HL et al (2023b) Macrophages promote anti-androgen resistance in prostate cancer bone disease. J Exp Med 220(4):e20221007. https:\/\/doi.org\/10.1084\/jem.20221007","journal-title":"J Exp Med"},{"issue":"9","key":"6276_CR39","doi-asserted-by":"publisher","first-page":"e007386","DOI":"10.1136\/jitc-2023-007386","volume":"11","author":"M Dahut","year":"2023","unstructured":"Dahut M, Fousek K, Horn LA et al (2023) Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis. J Immunother Cancer 11(9):e007386. https:\/\/doi.org\/10.1136\/jitc-2023-007386","journal-title":"J Immunother Cancer"},{"issue":"20","key":"6276_CR40","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1038\/s41388-022-02306-w","volume":"41","author":"Z Tan","year":"2022","unstructured":"Tan Z, Shi S, Xu J et al (2022) RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner. Oncogene 41(20):2860\u20132872. https:\/\/doi.org\/10.1038\/s41388-022-02306-w","journal-title":"Oncogene"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06276-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06276-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06276-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:46:50Z","timestamp":1761338810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06276-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6276"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06276-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The animal study was approved by the Animal Experiment Welfare and Ethics Committee of Army Medical University (AMUWEC20240071). The animal experimental protocol reported in this study was approved by the Institutional Animal Ethics Committee of the Army Medical University, China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"267"}}